| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected but not Quantified |
|---|
| Creation Date | 2007-04-12 20:54:27 UTC |
|---|
| Update Date | 2022-09-22 18:34:18 UTC |
|---|
| HMDB ID | HMDB0006036 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Mesterolone |
|---|
| Description | Mesterolone is a synthetic anabolic androgenic steroid (AAS) with reported abuses in human sports. As for other AAS, mesterolone is also a potential doping agent in equine sports. In humans, mesterolone exhibits no inhibitory effects on hypophysial gonadotropin secretion or on spermatogenesis, unlike most androgens. Mesterolone has been used in the treatment of primary nocturnal enuresis in boys six to ten years of age. Mesterolone probably modulates the autonomic innervation of the vesical musculature with correction of the defective neural mechanism which is believed to be implicated in the pathogenesis of nocturnal enuresis. Mesterolone has been utilized in hypogonadism patients to increase total ejaculation volume and the concentration of fructose in the spermatic plasma to normal levels. Mesterolone treatment decreases cholesterol, beta-lipoproteins, fatty acid esters, free fatty acids, triglycerides and glycerol in human serum. (PMID: 4880965 , 17616252 , 10796496 , 17636603 , 2087834 , 6111418 , 6142498 , 6386424 , 7558381 , 792898 ). |
|---|
| Structure | [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)C[C@H](C)[C@]12C InChI=1S/C20H32O2/c1-12-10-14(21)11-13-4-5-15-16-6-7-18(22)19(16,2)9-8-17(15)20(12,13)3/h12-13,15-18,22H,4-11H2,1-3H3/t12-,13-,15-,16-,17-,18-,19-,20-/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| Proviron | MeSH | | Vistimon | MeSH | | SH-723Mesterolone | ChEMBL, HMDB | | (1a,5a,17b)-17-Hydroxy-1-methyl-androstan-3-one | HMDB | | 17b-Hydroxy-1a-methyl-5a-androstan-3-one | HMDB | | 1a-Methyl-17b-hydroxy-5a-androstan-3-one | HMDB | | 1a-Methyl-5a-androstan-17b-ol-3-one | HMDB | | 1a-Methyl-5a-dihydrotestosterone | HMDB | | Androviron | HMDB | | Mesteranum | HMDB | | Mestoranum | HMDB | | Provirone 25 | HMDB | | SH 723 | HMDB | | Testiwop | HMDB | | Jenapharm brand OF mesterolone | MeSH, HMDB | | Schering brand OF mesterolone | MeSH, HMDB | | Mesterolone jenapharm brand | MeSH, HMDB | | Mesterolone schering brand | MeSH, HMDB |
|
|---|
| Chemical Formula | C20H32O2 |
|---|
| Average Molecular Weight | 304.4669 |
|---|
| Monoisotopic Molecular Weight | 304.240230268 |
|---|
| IUPAC Name | (1S,2S,3S,7S,10R,11S,14S,15S)-14-hydroxy-2,3,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-5-one |
|---|
| Traditional Name | proviron |
|---|
| CAS Registry Number | 1424-00-6 |
|---|
| SMILES | [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)C[C@H](C)[C@]12C |
|---|
| InChI Identifier | InChI=1S/C20H32O2/c1-12-10-14(21)11-13-4-5-15-16-6-7-18(22)19(16,2)9-8-17(15)20(12,13)3/h12-13,15-18,22H,4-11H2,1-3H3/t12-,13-,15-,16-,17-,18-,19-,20-/m0/s1 |
|---|
| InChI Key | UXYRZJKIQKRJCF-TZPFWLJSSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Lipids and lipid-like molecules |
|---|
| Class | Steroids and steroid derivatives |
|---|
| Sub Class | Androstane steroids |
|---|
| Direct Parent | Androgens and derivatives |
|---|
| Alternative Parents | |
|---|
| Substituents | - Androgen-skeleton
- 3-oxosteroid
- 3-oxo-5-alpha-steroid
- 17-hydroxysteroid
- Oxosteroid
- Hydroxysteroid
- Cyclic alcohol
- Cyclic ketone
- Secondary alcohol
- Ketone
- Organic oxygen compound
- Organooxygen compound
- Hydrocarbon derivative
- Carbonyl group
- Organic oxide
- Alcohol
- Aliphatic homopolycyclic compound
|
|---|
| Molecular Framework | Aliphatic homopolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 204 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 6.79 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 17.0226 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 2.22 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2716.7 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 448.8 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 218.7 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 195.4 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 509.4 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 709.6 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 748.7 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 84.3 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1317.5 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 491.9 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1567.6 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 412.6 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 458.7 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 243.9 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 425.0 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 11.8 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Mesterolone,1TMS,isomer #1 | C[C@H]1CC(=O)C[C@@H]2CC[C@H]3[C@@H]4CC[C@H](O[Si](C)(C)C)[C@@]4(C)CC[C@@H]3[C@@]12C | 2678.0 | Semi standard non polar | 33892256 | | Mesterolone,1TMS,isomer #2 | C[C@H]1C=C(O[Si](C)(C)C)C[C@@H]2CC[C@H]3[C@@H]4CC[C@H](O)[C@@]4(C)CC[C@@H]3[C@@]12C | 2610.2 | Semi standard non polar | 33892256 | | Mesterolone,1TMS,isomer #3 | C[C@H]1CC(O[Si](C)(C)C)=C[C@@H]2CC[C@H]3[C@@H]4CC[C@H](O)[C@@]4(C)CC[C@@H]3[C@@]12C | 2627.9 | Semi standard non polar | 33892256 | | Mesterolone,2TMS,isomer #1 | C[C@H]1CC(O[Si](C)(C)C)=C[C@@H]2CC[C@H]3[C@@H]4CC[C@H](O[Si](C)(C)C)[C@@]4(C)CC[C@@H]3[C@@]12C | 2652.8 | Semi standard non polar | 33892256 | | Mesterolone,2TMS,isomer #1 | C[C@H]1CC(O[Si](C)(C)C)=C[C@@H]2CC[C@H]3[C@@H]4CC[C@H](O[Si](C)(C)C)[C@@]4(C)CC[C@@H]3[C@@]12C | 2684.4 | Standard non polar | 33892256 | | Mesterolone,2TMS,isomer #1 | C[C@H]1CC(O[Si](C)(C)C)=C[C@@H]2CC[C@H]3[C@@H]4CC[C@H](O[Si](C)(C)C)[C@@]4(C)CC[C@@H]3[C@@]12C | 2943.8 | Standard polar | 33892256 | | Mesterolone,2TMS,isomer #2 | C[C@H]1C=C(O[Si](C)(C)C)C[C@@H]2CC[C@H]3[C@@H]4CC[C@H](O[Si](C)(C)C)[C@@]4(C)CC[C@@H]3[C@@]12C | 2632.5 | Semi standard non polar | 33892256 | | Mesterolone,2TMS,isomer #2 | C[C@H]1C=C(O[Si](C)(C)C)C[C@@H]2CC[C@H]3[C@@H]4CC[C@H](O[Si](C)(C)C)[C@@]4(C)CC[C@@H]3[C@@]12C | 2662.4 | Standard non polar | 33892256 | | Mesterolone,2TMS,isomer #2 | C[C@H]1C=C(O[Si](C)(C)C)C[C@@H]2CC[C@H]3[C@@H]4CC[C@H](O[Si](C)(C)C)[C@@]4(C)CC[C@@H]3[C@@]12C | 2947.5 | Standard polar | 33892256 | | Mesterolone,1TBDMS,isomer #1 | C[C@H]1CC(=O)C[C@@H]2CC[C@H]3[C@@H]4CC[C@H](O[Si](C)(C)C(C)(C)C)[C@@]4(C)CC[C@@H]3[C@@]12C | 2925.2 | Semi standard non polar | 33892256 | | Mesterolone,1TBDMS,isomer #2 | C[C@H]1C=C(O[Si](C)(C)C(C)(C)C)C[C@@H]2CC[C@H]3[C@@H]4CC[C@H](O)[C@@]4(C)CC[C@@H]3[C@@]12C | 2846.7 | Semi standard non polar | 33892256 | | Mesterolone,1TBDMS,isomer #3 | C[C@H]1CC(O[Si](C)(C)C(C)(C)C)=C[C@@H]2CC[C@H]3[C@@H]4CC[C@H](O)[C@@]4(C)CC[C@@H]3[C@@]12C | 2862.5 | Semi standard non polar | 33892256 | | Mesterolone,2TBDMS,isomer #1 | C[C@H]1CC(O[Si](C)(C)C(C)(C)C)=C[C@@H]2CC[C@H]3[C@@H]4CC[C@H](O[Si](C)(C)C(C)(C)C)[C@@]4(C)CC[C@@H]3[C@@]12C | 3183.8 | Semi standard non polar | 33892256 | | Mesterolone,2TBDMS,isomer #1 | C[C@H]1CC(O[Si](C)(C)C(C)(C)C)=C[C@@H]2CC[C@H]3[C@@H]4CC[C@H](O[Si](C)(C)C(C)(C)C)[C@@]4(C)CC[C@@H]3[C@@]12C | 3136.0 | Standard non polar | 33892256 | | Mesterolone,2TBDMS,isomer #1 | C[C@H]1CC(O[Si](C)(C)C(C)(C)C)=C[C@@H]2CC[C@H]3[C@@H]4CC[C@H](O[Si](C)(C)C(C)(C)C)[C@@]4(C)CC[C@@H]3[C@@]12C | 3190.7 | Standard polar | 33892256 | | Mesterolone,2TBDMS,isomer #2 | C[C@H]1C=C(O[Si](C)(C)C(C)(C)C)C[C@@H]2CC[C@H]3[C@@H]4CC[C@H](O[Si](C)(C)C(C)(C)C)[C@@]4(C)CC[C@@H]3[C@@]12C | 3157.8 | Semi standard non polar | 33892256 | | Mesterolone,2TBDMS,isomer #2 | C[C@H]1C=C(O[Si](C)(C)C(C)(C)C)C[C@@H]2CC[C@H]3[C@@H]4CC[C@H](O[Si](C)(C)C(C)(C)C)[C@@]4(C)CC[C@@H]3[C@@]12C | 3129.9 | Standard non polar | 33892256 | | Mesterolone,2TBDMS,isomer #2 | C[C@H]1C=C(O[Si](C)(C)C(C)(C)C)C[C@@H]2CC[C@H]3[C@@H]4CC[C@H](O[Si](C)(C)C(C)(C)C)[C@@]4(C)CC[C@@H]3[C@@]12C | 3193.0 | Standard polar | 33892256 |
|
|---|
| General References | - Petry R, Rausch-Stroomann JG, Hienz HA, Senge T, Mauss J: Androgen treatment without inhibiting effect on hypophysis and male gonads. Biochemical and morphological studies after treatment with Mesterolone. Acta Endocrinol (Copenh). 1968 Nov;59(3):497-507. [PubMed:4880965 ]
- Ho EN, Leung DK, Leung GN, Wan TS, Wong HN, Xu X, Yeung JH: Metabolic studies of mesterolone in horses. Anal Chim Acta. 2007 Jul 16;596(1):149-55. Epub 2007 Jun 3. [PubMed:17616252 ]
- Vandekerckhove P, Lilford R, Vail A, Hughes E: Androgens versus placebo or no treatment for idiopathic oligo/asthenospermia. Cochrane Database Syst Rev. 2000;(2):CD000150. [PubMed:10796496 ]
- Vandekerckhove P, Lilford R, Vail A, Hughes E: WITHDRAWN: Androgens versus placebo or no treatment for idiopathic oligo/asthenospermia. Cochrane Database Syst Rev. 2007 Jul 18;(4):CD000150. [PubMed:17636603 ]
- Schell H: [Objective assessment of therapeutic hair growth--methods, possibilities and problems]. Z Hautkr. 1990 Dec;65(12):1080-4. [PubMed:2087834 ]
- Cooper AJ: Short-term treatment in sexual dysfunction: a review. Compr Psychiatry. 1981 Mar-Apr;22(2):206-17. [PubMed:6111418 ]
- Itil TM: The discovery of antidepressant drugs by computer-analyzed human cerebral bio-electrical potentials (CEEG). Prog Neurobiol. 1983;20(3-4):185-249. [PubMed:6142498 ]
- Schill WB, Michalopoulos M: Treatment of male fertility disturbances. Current concepts. Drugs. 1984 Sep;28(3):263-80. [PubMed:6386424 ]
- Mbizvo MT: Functional motion changes during sperm transit to the site of fertilization and in-vitro applications: a review. Int J Androl. 1995 Jun;18 Suppl 1:1-6. [PubMed:7558381 ]
- Herrmann WM, Beach RC: Psychotropic effects of androgens: a review of clinical observations and new human experimental findings. Pharmakopsychiatr Neuropsychopharmakol. 1976 Sep;9(5):205-19. [PubMed:792898 ]
|
|---|